Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1

Details Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1

2006-04-18

2006-04-18

McKane, Joseph K. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S367000, C546S114000, C548S161000

Reexamination Certificate

active

07030135

ABSTRACT:
The present invention relates to using a compound having the formula (I) wherein T is I) thienyl, which optionally is substituted with halogen, or II) phenyl optionally substituted with halogen and/or C1-6-alkyl; E is a bond, —CH2— or —CO—; L is a bond, —CH2—, —CHR4— or —NR3—; R3is H, C1-6-alkyl, C1-6-acyl or —COR4; R4is morpholino or C1-6-amido; R6and R7are independently hydrogen or C1-6-alkyl; and R8and R9are independently hydrogen or C1-6-alkyl, as well as pharmaceutically acceptable salts, hydrates and solvates thereof, in the manufacture of a medicament for the treatment or prevention of diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, osteoporosis, tuberculosis, dementia, depression, virus diseases and inflammatory disorders.

REFERENCES:
patent: 2362087 (1944-11-01), Newbery
patent: 4254260 (1981-03-01), Takaya et al.
patent: 5403857 (1995-04-01), Edwards et al.
patent: 5594021 (1997-01-01), Chan et al.
patent: 5783597 (1998-07-01), Beers et al.
patent: 5856347 (1999-01-01), Hashiguchi et al.
patent: 5962490 (1999-10-01), Chan et al.
patent: 6030991 (2000-02-01), Chan et al.
patent: 2003/0130258 (2003-07-01), Kurz et al.
patent: 2003/0130279 (2003-07-01), Jang et al.
patent: 2003/0130318 (2003-07-01), Barf et al.
patent: 2003/0166689 (2003-09-01), Kurz et al.
patent: 2003/0176476 (2003-09-01), Barf et al.
patent: 0 749 964 (1996-12-01), None
patent: 0 790 057 (1997-08-01), None
patent: 0 819 681 (1998-01-01), None
patent: 1 069 114 (2001-01-01), None
patent: 94.123 (1969-05-01), None
patent: 2 384 498 (1978-10-01), None
patent: 620654 (1940-07-01), None
patent: 822 947 (1959-11-01), None
patent: 822947 (1959-11-01), None
patent: 6610324 (1969-01-01), None
patent: 2001483 (1990-01-01), None
patent: 03173876 (1991-07-01), None
patent: 2001483 (1994-03-01), None
patent: 6610324 (1967-01-01), None
patent: WO 96/04912 (1996-02-01), None
patent: WO 97/07789 (1997-03-01), None
patent: WO 98/16520 (1998-04-01), None
patent: WO 98/27081 (1998-06-01), None
patent: WO 98/36770 (1998-08-01), None
patent: WO 99/02502 (1999-01-01), None
patent: WO 99/28306 (1999-06-01), None
patent: WO 99/65884 (1999-12-01), None
patent: WO 00/02851 (2000-01-01), None
patent: WO 01/01971 (2001-01-01), None
patent: WO 01/52833 (2001-07-01), None
patent: WO 01/54691 (2001-08-01), None
patent: WO 01/90090 (2001-11-01), None
patent: WO 01/90091 (2001-11-01), None
patent: WO 02/28353 (2002-04-01), None
patent: WO 03/011258 (2003-02-01), None
Huff, Journal of Medicinal Chemistry, vol. 34, No. 8, pp. 2305-2314, (1991).
Hisamitsu Pharmaceutical Co: “Preparation of 2-(substituted amino)thiazole derivatives as esterase inhibitors,” CAPLUS Accession No. 1995:818696, Document No. 123:228174 (1995).
Hisamitsu Pharmaceutical Co: “Preparation of 2-aminothiazole derivatives as esterase inhibitors,” CAPLUS Accession No. 1995:867676, Document No. 123:256699 (1995).
Susan Budavari et al., “The Merck Index, An Encyclopedia of Chemical, Drugs, and Biologicals, Twelfth Edition,”, No. 9115, pp. 1529 (1996).
Friedrich Boberg et al., “Reaction of thioxo compounds with N-chloramidines. VI. Reaction of thioquinolone, dihydrothiazolethione and dihydroisothiazole thione with sodium N-chlorobenzenesulfonamides,” CAPLUS Accession No. 1996:420288, Document No. 125:195596 (1996).
CHEMCATS Accession No. 1998:584450, Maybridge, Apr. 3, 2000, (1998).
CHEMCATS Accession No. 1998:584451, Maybridge, Apr. 3, 2000, (1998).
Hisamitsu Pharmaceutical Co: “Preparation of 2-(substituted amino)thiazole derivatives as esterase inhibitors,” CAPLUS Accession No. 1995:818696, Document No. 123:228174 (1995).
Asahi Chemical Ind: “Therapeutics for Alzheimer's disease containing N-(5-nitro-2-thiazolyl)benzenesulfonamides,” CAPLUS Accession No. 1996:111694, Document No. 124:165271 (1996).
Hisamitsu Pharmaceutical Co: “Preparation of diphenylthiazoles as pharmaceuticals,” CAPLUS Accession No. 1991:680016, Document No. 115:280016, (1991).
Zaki El-Hewehi et al., “Sulfonic acid derivatives: preparation and applicability as mothproofing agents,” Chemical Abstracts, vol. 58, The Abstract No. 5671, J. Prakt.Chem., pp. 297-336 (1962).
AsInEx Compound Collection, “5-Thiazolecarboxylic acid, 4-methyl-2-(((4-methylphenyl)sulfonyl)amino)-, ethyl ester,” CHEMCATS Accession No. 2001:67657, (2001).
Pharma Library Collection, “5-Thiazolecarboxylic acid, 2-(((4-chlorophenyl)sulfonyl)amino)-4-methyl-, ethyl ester,” CHEMCATS Accession No. 2001:19109, (2001).
ChemDiv, Inc. Product Library, Apr. 26, 2001, “5-Thiazolecarboxylic acid, 4-methyl-2-(((4-methylphenyl)sulfonyl)amino-), ethyl ester,” CHEMCATS Accession No. 2001:444469, (2001).
V.V. Berezhinskaya, “hypoglycemic activity in relation to chem. Structure of potential oral antidiabetic substances—(I) 1-sulfonyl-3-alkylureas, (II) analogs of 1-sulfonyl-3-alkylureas, (III) 2-benzene-sulfonamido-5-alkyl-1,3,4-thiadiazole and-oxadiazoles,” CAOLD Accession No. CA57:3567g (1962).
Hans Wojahn, “Bromination of sulfapyrimidine and sulfathiazole compounds. II.,” Chemical Abstracts, vol. 51, The Abstract No. 6646d, Arch. Pharm., pp. 288, 321-336 (1955).
V.A. Krasovskii et al., “Alkylation of aminothiazoles. VII. Alkylation of 2-aminothiazole and 4-methyl-2-aminothiazole by tert-butyl alcohol,” CAPLUS Accession No. 1969:115051, Document No. 70: 115051, (1969).
J.D. McColl et al., “Effect of Some Sulfonylurea Deriviatives in Experimental Ulcer Formation in the Rat,” Chemical Abstracts, vol. 59, The Abstract No. 3231, Arch. Intern. Pharmacodyn, pp. 181-189 (1963).
Gaile E. Gudriniece et al., “Heterocyclic compounds based on diketones. II. 2′-Amino-5,5-dimethyl-1-cyclohexanone(2,3:4′,5″)thiazole. I.,” Chemical Abstracts, vol. 59, The Abstract No. 6380 (1962).
Anton-Fos et al., “Pharmacological Studies of the Two New Hypoglycaemic Compounds 4-(3-Methyl-5-oxo-2-pyrazolin-1-yl)benzoic Acid and 1-(Mesitylen-2-sulfonyl)-1H-1,2,4-triazole,” Arzneim.-Forsch./Drug Res 44(11), No. 7, 1994, pp. 821-826.
Merck & Co. Inc., USA, 1999, Monograph No. 4488, “Glybuzole,” CAS Registry No. 1492-02-0.
Merck & Co. Inc., USA, 1999, Monograph No. 9084, “Sulfamethizole,” CAS Registry No. 144-82-1.
CAPLUS, “2-Thiophenecarboxamide, N-2-naphthalenyl-3-((phenylsulfonyl)amino)-(9CI)”, Caplus Registry No. 409362-65-8. (Supplement to Reference AS) (2002).
CAPLUS, “2-Thiophenecarboxamide, N-1-naphthalenyl-3-((phenylsulfonyl)amino)-(9CI),” Caplus Registry No. 409363-57-1. (Supplement to Reference AS) (2002).
CAPLUS, “2-Thiophenecarboxamide, 3-((phenylsulfonyl)amino)-N-(3-thienylmethyl)- (9CI),” Caplus Registry No. 409363-56-0. (Supplement to Reference AY) (1969).
CAPLUS, “2-Thiophenecarboxamide, 3-((phenylsulfonyl)amino)-N-(2-thienylmethyl)- (9CI),”, Caplus Registry No. 409362-88-5. (Supplement to Reference AS) (2002).
CAPLUS, “2-Thiophenecarboxamide, N-(2-phenylethyl)-3-((phenylsulfonyl)amino)- (9CI),”, Caplus Registry No. 409362-99-8. (Supplement to Reference AS) (2002).
CAPLUS, “2-Thiophenecarboxamide, N-(2,3-dimethylphenyl)-3-((phenylsulfonyl)amino)- (9CI),” Caplus Registry No. 409362-97-6. (Supplement to Reference AY) (1969).
CAPLUS, “2-Thiophenecarboxamide, N-(4-ethylphenyl)-3-((phenylsulfonyl)amino)- (9CI),” Caplus Registry No. 409362-93-2. (Supplement to Reference AS) (2002).
CAPLUS, “2-Thiophenecarboxamide, N-(2,6-dimethylphenyl)-3-((phenylsulfonyl)amino)- (9CI),” Caplus Registry No. 409362-72-7. (Supplement to Reference AS) (2002).
CAPLUS, “2-Thiophenecarboxamide, N-butyl-3-((phenylsulfonyl(amino)- (9CI),” Caplus Registry No. 409362-91-0. (Supplement to Reference AS) (2002).
CAPLUS, “2-Thiophenecarboxamide, N-(2-met

Affiliated with

Also associated with

Rating

Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3588970